[Comparison evaluation of cost-effectiveness in bronchial asthma patients].
A choice of a proper drug and method for clinically successful therapy in patients with bronchial asthma has to be based on results of experimental and clinical studies and cost analysis. Some problems connected with cost-effectiveness analysis are presented in relation to glucocorticosteroids, agonist of beta2-adrenoreceptors and allergen-specific immunotherapy.
Płusa
T
T
Kliniki Chorób Wewnetrznych, Pneumonologii i Alergologii Instytutu Medycyny Wewnetrznej Centralnego Szpitala Klinicznego Wojskowej Akademii Medycznej w Warszawie.
Jahnz-Rózyk
K
K
D000318:Adrenergic beta-Agonists / Q000191:economics / Q000627:therapeutic use; D001249:Asthma / Q000191:economics* / Q000628:therapy; D003362:Cost-Benefit Analysis; D005938:Glucocorticoids / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy
D000318:Adrenergic beta-Agonists; D005938:Glucocorticoids